Jeffrey N Hemenway

This inventor holds 7 USPTO granted patents and 2 published patent applications, plus 2 CIPO patents and 1 EPO patent. Top assignees: Gilead Sciences, Inc., Sierra Oncology, Inc., Glaxosmithkline LLC. Active years: 2016-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jeffrey N Hemenway. Retrieved from https://idiyas.com/inventor/jeffrey-n-hemenway

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 7 (Patent Applications = 2)

% Patents Active = 100.0

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 1 (Patent Applications = 4)

Average Co-Inventor Count = 10.7

ph-index = 2

Forward Citations = 17(Granted Patents)

Company Filing History:

4 out of 946

Gilead Sciences, Inc.

patents

2 out of 4

Sierra Oncology, Inc.

Years Active: 2016-2025

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. RE50497 - (N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide (2025-07-22),

2. 12102625 - Solid forms of FXR agonists (2024-10-01),

3. RE49445 - N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide (2023-03-06),

4. 11524005 - Solid forms of FXR agonists (2022-12-13),

5. RE48285 - N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide (2020-10-26),

6. 9809559 - (N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide (2017-11-07),

7. 9469613 - (N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide (2016-10-18),

Certainly! Here is the article about inventor Jeffrey N Hemenway:

Title: Unveiling the Ingenious Inventor: Jeffrey N Hemenway

Introduction: Meet Jeffrey N Hemenway, a prolific inventor based in the vibrant city of San Mateo, California, with a remarkable track record in the field of pharmaceutical innovations.

Latest Patents: Jeffrey N Hemenway recently secured two groundbreaking patents. The first patent pertains to stable novel salt forms of N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide, showcasing their utility in the preparation of pharmaceutical formulations. The second patent unveils novel solid forms of FXR agonists, crucial for treating conditions mediated by FXR.

Career Highlights: Having contributed significantly to the industry, Jeffrey has lent his expertise to renowned companies like Gilead Sciences, Inc. and Sierra Oncology, Inc., where he played a pivotal role in driving innovation and advancements in pharmaceuticals.

Collaborations: Along his journey, Jeffrey N Hemenway has collaborated with esteemed professionals such as Ernest A Carra and Bing Shi, fostering a culture of creativity and excellence in the realm of pharmaceutical inventions.

Conclusion: In essence, Jeffrey N Hemenway stands as a beacon of innovation, with his patents and contributions paving the way for transformative developments in the pharmaceutical landscape. His dedication and inventive spirit continue to inspire and shape the future of pharmaceutical research and development.

I hope you find this article about Jeffrey N Hemenway informative and engaging! If you have any more requests or need further information, feel free to ask!

Profile summary based on public USPTO records.